Puma Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
H.C. Wainwright Maintains Puma Biotechnology(PBYI.US) With Buy Rating, Maintains Target Price $7
Puma Biotechnology: A Buy Rating Reinforced by Strong Q2 Performance and Solid Prospects for Flagship Product Nerlynx
Barclays Maintains Puma Biotechnology(PBYI.US) With Sell Rating, Maintains Target Price $2
Barclays Sticks to Its Sell Rating for Puma Biotechnology (PBYI)
TD Cowen Maintains Puma Biotechnology(PBYI.US) With Hold Rating, Maintains Target Price $4
Puma Biotechnology: Hold Rating Justified by Sales Concerns and Financial Strain
Puma Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
H.C. Wainwright Maintains Puma Biotechnology(PBYI.US) With Buy Rating, Maintains Target Price $7
Optimistic Outlook for Puma Biotechnology: Buy Rating Justified by Strong Product Performance and Promising Pipeline
Puma Biotechnology Analyst Ratings
Puma Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
Buy Rating Reaffirmed for Puma Biotechnology Amid Promising Alisertib Developments and Orphan Drug Designation
HC Wainwright & Co. : The Puma Biotechnology (PBYI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.
Puma Biotechnology Analyst Ratings
TD Cowen Sticks to Its Hold Rating for Puma Biotechnology (PBYI)
Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR), Puma Biotechnology (PBYI) and Patterson Companies (PDCO)